Navigation Links
Allscripts Announces Second Quarter 2012 Results
Date:8/8/2012

price, and economic and market conditions. The Company's stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.

In June 2012, the Company obtained $150 million in the form of an incremental term loan, which was used to partially repay borrowings under the Company's existing revolving credit facility, previously used to fund the Company's share repurchases in the second quarter of 2012. 

During the second quarter of 2012, Allscripts repaid approximately $29.5 million of borrowings under its senior secured credit facilities.
As of June 30, 2012, the Company had $488 million of borrowings outstanding and cash and marketable securities of approximately $122 million.

Updated Annual Guidance, Reflects Revised Share CountAllscripts has revised its financial guidance for 2012 as detailed below to reflect the impact of a reduction in shares outstanding and increase in borrowings associated with the stock repurchase activity.  Please see the footnotes at the end of this release for a reconciliation of GAAP and non-GAAP financial presentations and other information.

2012 Guidance(2)Non-GAAP Revenue$1,480.0 to $1,520.0 millionNon-GAAP Operating Margin16.0 to 17.0 percentEffective Tax Rate36.5 to 37.0 percentNon-GAAP Diluted EPS$0.77 to $0.83 (Prior $0.74 to $0.80)Diluted Shares182.0 million (Prior 194.0)Conference CallAllscripts will conduct a conference call today, Wednesday, August 8, 2012, at 4:30 PM Eastern Daylight Time to discuss the Company's earnings and other information.
Investors can access the conference via the Internet at http://investor.allscripts.com.  Participants also may access the conference call by dialing (877) 303-0543 (toll free in the US) or (973) 935-8787 (international) and requesting Conference ID #97854516.

A replay of the call will be available two hours after the conclusion of the call, for a period of two
'/>"/>

SOURCE Allscripts Healthcare Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Allscripts Adds Two Independent Directors to Board
2. Developers: Deadline Approaching for Allscripts Million Hearts CDS Challenge
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
10. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
11. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Quebec , Sept. 30, 2014 Valeant ... TSX: VRX) today announced that the company,s ... Letter from the U.S. Food and Drug Administration (FDA) ... Company,s records with regards to Sculptra Aesthetic injectable, which ... Warning Letter pertains to the management of Valeant,s contract manufacturers ...
(Date:9/30/2014)... , Sept. 30, 2014  HealthLoop® released an ... with HealthKit in iOS 8 and allows people to ... The app harnesses native iOS technologies to enhance the ... a robust connection with their doctors between visits. ... and the data they collect is exciting," says HealthLoop ...
(Date:9/30/2014)... MOUNTAIN VIEW, Calif. , Sept. 30, 2014 ... oncology tissue diagnostics market, Frost & Sullivan recognizes ... the Roche Group, with the 2014 North American ... Adherence to strict quality practices along with a ... made Ventana a global leader in tissue-based cancer ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4
... and Drug Administration today issued new guidance that advises ... to administer influenza vaccinations. Based on this advice, The ... use of such clinical devices at all pharmacies and ... family of pharmacies and The Little Clinic locations will ...
... 21, 2011 Boca Pharmacal, Inc., today announced that it ... Drug Application (ANDA) for Glycopyrrolate Tablets USP, 1 mg and ... and Robinul Forte Tablets, 2 mg, distributed by Shionogi Pharma, ... in the treatment of peptic ulcers. "We,re up ...
Cached Medicine Technology:Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets 2
(Date:9/30/2014)... University of Maryland-led research team has been awarded ... Institutes of Health (NIH) to develop new imaging ... our understanding of how large networks of neurons ... This knowledge will help researchers identify the precise ... behavior, like decision-making and speaking, and alterations in ...
(Date:9/30/2014)... Elevate , the latest product from ... and out of the gym by providing natural ingredients that ... of Shane Michaels, prompting an investigative review. , “When ... most people simply just don’t have the ability to perform ... work, getting the motivation to finish a project, or even ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Hospice ... its annual “In Celebration” gala, honoring three outstanding ... mission of striving to provide extraordinary and dignified ... facing a serious or life-limiting illness. , The ... in Rye, NY and recognized William (Bill) J. ...
(Date:9/30/2014)... Dr. Karl R.O.S. Johnson, DC, has ... of care that is dramatically improving the health and ... Neurology & Nutrition—applies a proprietary, multi-dimensional approach that goes ... sources of inflammation, neurology of the joint and neurology ... the brain to the spine, to the legs, knees ...
(Date:9/30/2014)... 2014) Levothyroxine is considered the gold standard therapy ... review of therapies for the condition including combining ... assessment, say a team of investigators.,1Their analysis, published as ... , finds insufficient consistent data exist to recommend a ... sold under various trade names, such as Synthroid ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2
... that the U.S. Food and Drug Administration has approved ... prostate cancer patients, marks the beginning of an era ... the standard therapeutic arsenal against cancer, say Dana-Farber Cancer ... effectiveness in patients. The study the results ...
... ... Illness (NAMI), NAMIWalks help raise funds for local programs. , ... (PRWEB) -- May is Mental Health Month. This weekend, Saturday ... NAMIWalks to raise public awareness about facts concerning mental illness and the ...
... from all drugs used to prevent organ rejection, researchers ... type of drug treatment used to prevent organ rejection ... new study finds. , Kidney transplant patients are at ... use of immunosuppressive drugs to prevent organ rejection. In ...
... ... gastroenterologists from around the world to launch the first international “World IBD Day” dedicated ... conference (May 2 -5) in New Orleans. , ... New York, New York (Vocus) April 29, 2010 -- ...
... of ill people triggered greater response than pictures of gun-wielding ... a sick person may give your immune system a boost, ... sets of slides on two different days. The first set ... either a slideshow that showed photos of people with pox, ...
... This release is available in French . ... in Immunology and Cancer (IRIC) of the Universit de Montral ... ribonucleic acid (RNA) engineering laboratory in Canada. Led by Franois ... of Gerardo Ferbeyre, biochemistry researcher with the Faculty of Medicine ...
Cached Medicine News:Health News:Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments 2Health News:Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments 3Health News:NAMIWalks Kicks-off “Mental Health Month”; Fun Events that Support Serious Work 2Health News:Cancer Risk After Kidney Transplant Unaffected by Type of Drug Treatment 2Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 2Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 3Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 4Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 5Health News:Cells programmed to cure and even prevent cancer 2
... Streptavidin magnetic beads are designed ... biotinylated molecules such as DNA, ... cell lysates or hybridization reactions. ... dispersed, it can also be ...
... Streptavidin magnetic beads are ... covalently coupled to a ... substrates can be useful ... experiments including mRNA isolation ...
... For the detection P.falciparum ... and pan specific pLDH, for differentiation ... other malarial species viz P.vivax ... P. malariae and for the ...
The Cellabs Rapimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by P. falciparum at the merozoite (red blood cell) stage o...
Medicine Products: